--- title: "Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings" type: "News" locale: "en" url: "https://longbridge.com/en/news/283154648.md" description: "Abbott Laboratories (NYSE:ABT) reported strong Q1 earnings but lowered its 2026 outlook, citing dilution from the Exact Sciences acquisition. Q1 sales reached $11.16 billion, surpassing expectations, with adjusted earnings of $1.15 per share. However, the company revised its 2026 earnings forecast down to $5.38-$5.58 per share, below Wall Street's consensus. Analysts have adjusted their price targets for Abbott, with several maintaining a Buy rating but lowering targets to $120. Abbott shares fell 0.1% to close at $95.47." datetime: "2026-04-17T13:21:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283154648.md) - [en](https://longbridge.com/en/news/283154648.md) - [zh-HK](https://longbridge.com/zh-HK/news/283154648.md) --- # Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings **Abbott Laboratories** (NYSE:ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations. The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion. Abbott reported adjusted earnings of $1.15 per share, beating the Wall Street estimate of $1.14 and management guidance of $1.12-$1.18 per share. The global healthcare company on Thursday said it expects the second quarter of 2026 adjusted earnings of $1.25-$1.31, below the consensus of $1.37. Abbott lowered its fiscal 2026 adjusted earnings from $5.55-$5.80 per share to $5.38-$5.58 per share compared to the Wall Street consensus of $5.62. The updated guidance includes 20 cents per share of dilution related to the acquisition of Exact Sciences. The company projects fiscal 2026 comparable sales growth of 6.5% to 7.5%. Robert Ford, Chairman and CEO of Abbott, said, "We forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate." Abbott shares slipped 0.1% to close at $95.47 on Thursday. These analysts made changes to their price targets on Abbott following earnings announcement. - Stifel analyst Rick Wise maintained Abbott with a Buy and lowered the price target from $145 to $120. - B of A Securities analyst Travis Steed maintained the stock with a Buy and lowered the price target from $150 to $120. - Evercore ISI Group analyst Vijay Kumar maintained Abbott with an Outperform rating and cut the price target from $134 to $120. - Benchmark analyst Bruce D. Jackson maintained the stock with a Buy and lowered the price target from $145 to $120. **Considering buying ABT stock? Here’s what analysts think:** Photo via Shutterstock ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [EVR.US](https://longbridge.com/en/quote/EVR.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Harvest Portfolios Group Inc. Grows Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/287027124.md) - [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Rayburn West Financial Services LLC Buys Shares of 16,587 Abbott Laboratories $ABT](https://longbridge.com/en/news/286395934.md)